CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project focuses on developing RNA-based therapies for cancer treatment, particularly for acute myeloid leukemia and uveal melanoma. By enhancing tumor immune responses and creating personalized mRNA vaccines, it aims to provide new options for patients who currently lack effective immunotherapy.
In the past five years, RNA therapeutics have witnessed a true revolution.
Several RNA-based therapies have been approved for the treatment of genetic diseases, with unprecedented successes, as in spinal muscular atrophy.
Moreover, the past year showed the world that RNA-based therapies, namely mRNA vaccines, can be the answer to a worldwide pandemic and save the lives of millions. RNA therapies are however lagging behind in clinical oncology.
The overarching aim of this multi-armed project is t…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Israel, Ramat Gan
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Israel, SHAVE ZION
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
THE HEBREW UNIVERSITY OF JERUSALEM
Israel, Jerusalem
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
Guests see up to 5 keywords.
